This Anascorp market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth during the historic period can be attributed to the prevalence of scorpion stings, increased awareness of the risks associated with scorpion venom, medical advancements in emergency care, regional scorpion population growth, and regulatory approvals.
Market growth during the forecast period can be attributed to rising incidence of scorpion stings due to climate change, government initiatives for public health in endemic regions, rising awareness of antivenom treatments, expansion of distribution channels, and healthcare infrastructure improvements in emerging markets. Major trends in the forecast period include advancements in antivenom production technologies, the development of mRNA vaccines and therapeutics, a focus on sustainability and long-term solutions, advancements in cell and gene therapies, and the integration of artificial intelligence (AI) and machine learning (ML).
The increasing number of snakebite incidents is expected to drive the growth of the anascorp market in the coming years. Snakebite incidents occur when a person is bitten by a venomous snake, which can lead to serious health complications that require immediate medical attention. The rise in these incidents is largely attributed to urbanization, climate change, human encroachment on snake habitats, limited access to healthcare, and a lack of awareness and preventive measures. Anascorp, an innovative antivenom, treats snakebites by neutralizing the venom from certain venomous snakes, thus reducing the risk of severe symptoms, organ damage, or death. It is especially beneficial in regions where snakebites are common, offering timely and effective treatment. For example, the World Health Organization (WHO) reported in September 2023 that around 5.4 million snakebites occur annually, leading to 81,410 to 137,880 deaths and many permanent disabilities. As snakebite incidents increase, the demand for anascorp is growing.
The rising incidence of infectious diseases is expected to fuel the growth of the anascorp market. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, are becoming more common due to increased global travel, which facilitates the spread of pathogens, and declining vaccination rates, which contribute to the resurgence of preventable diseases such as measles. Anascorp is used to treat venomous snakebites by neutralizing the venom, thus preventing severe systemic effects and potential infections from tissue damage. For instance, the UK Health Security Agency (UKHSA) reported 368 cases of measles in England in 2023, a nearly sevenfold increase from the 53 cases in 2022. This rise in infectious diseases is contributing to the growth of the anascorp market.
A key trend in the anascorp market is the development of innovative solutions, such as advancements in scorpion sting treatments, to improve therapeutic efficacy and patient outcomes. Scorpion sting treatments aim to alleviate the symptoms and complications caused by venomous scorpion stings. For example, in November 2023, the Institute of Advanced Studies in Science and Technology in India developed a novel therapeutic drug formulation (TDF) to enhance the treatment of Indian red scorpion stings, which pose a significant health risk in India. This new formulation combines low doses of commercial equine anti-scorpion antivenom, α1-adrenoreceptor agonists, and vitamin C to effectively counteract the venom's toxicity. Research showed that the TDF significantly outperformed traditional treatments in laboratory models by reducing harmful effects such as elevated blood glucose and organ damage.
The key company operating in the anascorp market is Instituto Bioclon S.A. de C.V.
North America was the largest region in the anascorp market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anascorp report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anascorp market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Anascorp is a biopharmaceutical product used as a therapeutic antivenom to treat scorpion venom toxicity, particularly from dangerous species of Centruroides. Its production involves biological manufacturing processes, providing essential treatment for individuals experiencing severe reactions to scorpion stings.
The main types of products in anascorp include human antivenoms, veterinary antivenoms, and combination antivenoms. Human antivenoms are specifically formulated to treat venomous bites or stings in humans. The clinical indications for Anascorp include scorpion stings and snake bites. It is distributed through various sales channels, including direct sales, wholesalers, and online pharmacies, and is used by a wide range of patients, including adults, geriatric patients, and pediatrics.
The anascorp market research report is one of a series of new reports that provides anascorp market statistics, including anascorp industry global market size, regional shares, competitors with an anascorp market share, detailed anascorp market segments, market trends and opportunities, and any further data you may need to thrive in the anascorp industry. This anascorp market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anascorp market consists of sales of products including Biosidus, ImmuVenom, Vins Bioproducts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth during the historic period can be attributed to the prevalence of scorpion stings, increased awareness of the risks associated with scorpion venom, medical advancements in emergency care, regional scorpion population growth, and regulatory approvals.
Market growth during the forecast period can be attributed to rising incidence of scorpion stings due to climate change, government initiatives for public health in endemic regions, rising awareness of antivenom treatments, expansion of distribution channels, and healthcare infrastructure improvements in emerging markets. Major trends in the forecast period include advancements in antivenom production technologies, the development of mRNA vaccines and therapeutics, a focus on sustainability and long-term solutions, advancements in cell and gene therapies, and the integration of artificial intelligence (AI) and machine learning (ML).
The increasing number of snakebite incidents is expected to drive the growth of the anascorp market in the coming years. Snakebite incidents occur when a person is bitten by a venomous snake, which can lead to serious health complications that require immediate medical attention. The rise in these incidents is largely attributed to urbanization, climate change, human encroachment on snake habitats, limited access to healthcare, and a lack of awareness and preventive measures. Anascorp, an innovative antivenom, treats snakebites by neutralizing the venom from certain venomous snakes, thus reducing the risk of severe symptoms, organ damage, or death. It is especially beneficial in regions where snakebites are common, offering timely and effective treatment. For example, the World Health Organization (WHO) reported in September 2023 that around 5.4 million snakebites occur annually, leading to 81,410 to 137,880 deaths and many permanent disabilities. As snakebite incidents increase, the demand for anascorp is growing.
The rising incidence of infectious diseases is expected to fuel the growth of the anascorp market. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, are becoming more common due to increased global travel, which facilitates the spread of pathogens, and declining vaccination rates, which contribute to the resurgence of preventable diseases such as measles. Anascorp is used to treat venomous snakebites by neutralizing the venom, thus preventing severe systemic effects and potential infections from tissue damage. For instance, the UK Health Security Agency (UKHSA) reported 368 cases of measles in England in 2023, a nearly sevenfold increase from the 53 cases in 2022. This rise in infectious diseases is contributing to the growth of the anascorp market.
A key trend in the anascorp market is the development of innovative solutions, such as advancements in scorpion sting treatments, to improve therapeutic efficacy and patient outcomes. Scorpion sting treatments aim to alleviate the symptoms and complications caused by venomous scorpion stings. For example, in November 2023, the Institute of Advanced Studies in Science and Technology in India developed a novel therapeutic drug formulation (TDF) to enhance the treatment of Indian red scorpion stings, which pose a significant health risk in India. This new formulation combines low doses of commercial equine anti-scorpion antivenom, α1-adrenoreceptor agonists, and vitamin C to effectively counteract the venom's toxicity. Research showed that the TDF significantly outperformed traditional treatments in laboratory models by reducing harmful effects such as elevated blood glucose and organ damage.
The key company operating in the anascorp market is Instituto Bioclon S.A. de C.V.
North America was the largest region in the anascorp market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anascorp report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anascorp market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Anascorp is a biopharmaceutical product used as a therapeutic antivenom to treat scorpion venom toxicity, particularly from dangerous species of Centruroides. Its production involves biological manufacturing processes, providing essential treatment for individuals experiencing severe reactions to scorpion stings.
The main types of products in anascorp include human antivenoms, veterinary antivenoms, and combination antivenoms. Human antivenoms are specifically formulated to treat venomous bites or stings in humans. The clinical indications for Anascorp include scorpion stings and snake bites. It is distributed through various sales channels, including direct sales, wholesalers, and online pharmacies, and is used by a wide range of patients, including adults, geriatric patients, and pediatrics.
The anascorp market research report is one of a series of new reports that provides anascorp market statistics, including anascorp industry global market size, regional shares, competitors with an anascorp market share, detailed anascorp market segments, market trends and opportunities, and any further data you may need to thrive in the anascorp industry. This anascorp market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anascorp market consists of sales of products including Biosidus, ImmuVenom, Vins Bioproducts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Anascorp Market Characteristics4. Anascorp Market Trends and Strategies5. Anascorp Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Anascorp Pricing Analysis & Forecasts30. Global Anascorp Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Anascorp Market32. Recent Developments in the Anascorp Market
3. Anascorp Market Biologic Drug Characteristics
6. Global Anascorp Growth Analysis and Strategic Analysis Framework
8. Anascorp Market Segmentation
9. Global Anascorp Epidemiology of Clinical Indications
10. Anascorp Market Regional and Country Analysis
11. Asia-Pacific Anascorp Market
12. China Anascorp Market
13. India Anascorp Market
14. Japan Anascorp Market
15. Australia Anascorp Market
16. South Korea Anascorp Market
17. Western Europe Anascorp Market
18. UK Anascorp Market
19. Germany Anascorp Market
20. France Anascorp Market
21. Eastern Europe Anascorp Market
22. North America Anascorp Market
23. USA Anascorp Market
24. Canada Anascorp Market
25. South America Anascorp Market
26. Middle East Anascorp Market
27. Africa Anascorp Market
28. Anascorp Market Competitive Landscape and Company Profiles
29. Global Anascorp Market Pipeline Analysis
33. Anascorp Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Anascorp Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on anascorp market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for anascorp? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anascorp market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Product: Human Antivenoms; Veterinary Antivenoms; Combination Antivenoms2) by Clinical Indication: Scorpion Stings; Snake Bites
3) by Distribution Channel: Direct Sales; Wholesalers; Online Pharmacies
4) by End-User: Adult; Geriatric; Pediatric
Key Companies Mentioned: Instituto Bioclon S.a. de C.V.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Instituto Bioclon S.A. de C.V.
